Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

S&P 500, Nasdaq Hit Fresh 52-Week Highs As Inflation Fears Ebb; Salesforce, Delta, JPMorgan In Focus: Weekly Review

The S&P 500 and Nasdaq led a strong market rally this week as inflation fears wane. Salesforce, Delta Air Lines, JPMorgan were key newsmakers

Investors Business Daily

The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?

An overweight world is hungry for obesity treatments, driving big forecasts for weight loss drugs. For now, two pharmaceutical stocks own the market.

Investors Business Daily

The Damaging Report That Sent Weight-Loss Kingpins Novo Nordisk, Eli Lilly Into A Tailspin

Eli Lilly stock and Novo Nordisk stock skidded Tuesday on a report most patients taking weight loss drugs like Wegovy stopped within a year.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Ozempic under EU investigation over reports of suicidal thoughts

Three cases of suicidal and self-harm thoughts identified in Iceland, regulator says

The Independent UK

Ozempic shortages in the UK may last until 2024 – here’s why

A global shortage means some people with diabetes are struggling to access the drug semaglutide, which is sold under the brand name Ozempic.

The Conversation

Investigation into risk of suicidal and self-harm thoughts among users of Wegovy, Saxenda and other weight loss jabs

It will also look at one used to for type 2 diabetes

Wales Online

Drug regulator investigating suicidal thoughts among some weight-loss jab users

The European Medicines Agency is looking at Wegovy (semaglutide), Saxenda (liraglutide) and other similar drugs used to control appetite.

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Popular UK-approved weight-loss drugs being investigated in Europe for suicide risk

Three cases of suicidal and self-harm thoughts identified in Iceland, regulator says

The Independent UK

Ozempic isn't alone. A whole class of 'revolutionary' weight-loss drugs is on the market—but only for the wealthy

“We're experiencing something here that is very, very different, very exciting from a healthcare perspective, and very expensive,” says Aon's Michael Manolakis.

Fortune

Investors Seek Improved Weight-Loss Drugs With Focus On Nausea-Free Alternatives To Wegovy

Zenger

Why Lilly's Obesity Treatment Update Sent Novo, Madrigal And Viking Shares Diving

Eli Lilly stock surged closer to a record high Tuesday after the company set a new bar in the industry for weight-loss medications.

Investors Business Daily

Pfizer Stock Tumbles On 'A Big Setback' In Obesity Treatment Vs. Novo Nordisk, Eli Lilly

Pfizer stock toppled Monday after the company tossed out a potential diabetes and weight-loss drug that leads to elevated liver enzymes.

Investors Business Daily

No more needles? A daily pill may work as well as Wegovy shots to treat obesity

Losing significant amounts of weight may soon be as easy as taking a daily pill

The Independent UK

Ozempic maker now wants to keep people from becoming obese in the first place

Novo Nordisk is investing in obesity prevention, the 'real big frontier' of weight loss.

Fortune

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

Diet Drug Manufacturer Sues Alleged Knockoff US Competitors

Custom-made versions of Ozempic are hitting the weight loss and that could be thinning out Novo Nordisk's profits.

StockNews.com

Diabetes Epidemic Makes this Stock a Strong Buy

Diabetes is a growing concern as more of the globe becomes modernized and with that is eating a diet that too often is a road to diabetes. Gladly there are drug companies at the forefront of this movement to stem the tide like Novo Nordisk (NVO) making it a very…

The Conversation

Semaglutide: beware of buying the weight-loss drug online

A few years ago, celebrity weight-control practices were out of most people’s reach. Live-in chefs and personal trainers, not to mention elaborate surgical procedures like the Brazilian butt lift, were not real options for most. But with the advent of drugs such as semaglutide, it seems that anyone can go…

Woman & Home

Wegovy is "not a magic bullet" - 3 doctors reveal what you need to know as the drug is set to be prescribed in the UK

As Wegovy is set to be available on prescription in the UK, we asked doctors what they think of the controversial weight loss injections

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Tilray Brands (TLRY) vs. Novo Nordisk (NVO): Which Pharma Stock Should You Buy?

The pharmaceutical sector performs relatively well during economic uncertainties due to inelastic demand for its products and services. While prominent players Tilray Brands (TLRY) and Novo Nordisk (NVO) should benefit, which stock is the better buy now? Read more to find out.

Investors Business Daily

One Of The Biggest Names In Medicine Just Entered The Obesity Melee. Here's Why Novo, Lilly Still Have An Edge.

Pharma giant Merck unveiled new data for a potential competitor to weight loss drugs from Novo Nordisk and Eli Lilly.

Marie Claire

A diabetes drug is going viral for its supposed weight loss benefits—but there’s a seriously dark problem here

Searches for weight loss injections have soared by 134%.

Chronicle Live

How the new 'game-changing' weight loss drug works, who is eligible and when it will be available in UK

The National Institute for Health and Care Excellence gave approval for the use of appetite suppressant Wegovy (semaglutide) earlier this year - here are more details about it

The Independent UK

How does Wegovy work? The ‘game changing’ weight loss drug beloved by Hollywood

Ministers have announced plans which could see tens of thousands given access to new weight-loss drug

Barchart

Why You Should Go Overweight On Novo Nordisk Stock

Novo Nordisk is already the global kingpin in diabetes treatments, with about 30% of the $50+ billion global diabetes market and around half of the $20 billion insulin therapy market. Now, it is becoming a powerhouse in weight-loss drugs, thanks to its Wegovy drug.

LiveScience

Watch out for Ozempic copycats containing unauthorized active ingredients, FDA warns

Some compounding pharmacies are using unauthorized active ingredients to make copycat versions of Ozempic and Wegovy.

1 … 13 14 15 16

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.